| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2982
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J7-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J9-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J9-00 |
| filingDate |
2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013544267-A |
| titleOfInvention |
Optimal synthesis of pure nonpolymorphic crystalline bile acids with a given particle size |
| abstract |
The present invention relates to pure polymorphs of Nor-UDCA, Bis-nor-UDCA or pharmaceutically acceptable salts thereof. The invention further provides pharmaceutical compositions comprising the polymorphs of the invention and methods for preparing the polymorphs of the invention. The invention includes the use of a polymorph or pharmaceutical composition of the invention as a medicament. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017081989-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7266588-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020535179-A |
| priorityDate |
2010-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |